Brookline Capital Acquisition Shareholders Approve Deadline Extension on Apexigen Deal

Brookline Capital Acquisition shareholders voted in favor of pushing the SPAC’s merger deadline back to Nov. 2 to allow more time to complete a business combination with Apexigen, a clinical-stage biopharmaceutical company.

Redemptions ahead of the shareholder vote erased 12% of Brookline’s trust, the SPAC disclosed in a regulatory filing. Following the redemptions, approximately $51.1 million remains in trust.

There is no minimum cash condition for closing this deal, according to the S-4 filed earlier this month (p. 41).

The Apexigen deal values the merged enterprise at $205 million.

As announced in March, terms call for gross proceeds to the combined of approximately $73 million. At the time, that amount included the $58 million in in Brookline Capital’s trust and $15 million from a fully committed PIPE that includes participation from healthcare institutional and individual investors. This does not include proceeds from Lincoln Park Capital’s $50 million committed equity line. Read more.

Total
0
Shares
Related Posts
Read More

Integrated Rail and Resources Files for $275M IPO

The new SPAC in the filing said its focus is on North American railroad companies that transport bulk commodities, terminal companies that transload bulk commodities to and from railroads and pipelines, trucks, and ports, the companies that produce bulk commodities moved by railroads in large volumes, and the rail cars that are used to transport bulk commodities.